Integrating 2D and 3D screening increases breast cancer detection and may lower reports of false positives.
Integrated 2D and 3D mammography improves breast-cancer detection and may reduce false positive recalls, according to a study published in The Lancet Oncology.
Conventional 2D mammography for breast cancer screening has limitations in both detecting cancer and producing false positive results. To address this issue, researchers from Italy and Australia investigated how integration of 2D and 3D mammography may improve cancer detection. This has been looked in a few smaller studies, but this is the largest completed trial that reported on the effectiveness of 3D screening in a larger group.
A total of 7,292 women, median age 58, were screened. Readings were first done with 2D imaging alone and then with integrated 2D and 3D mammography, resulting in paired data for each screening.
The researchers were looking at final assessment or excision histology. Primary outcome measures were the number of detected cancers, the number and proportion of false positive recalls, and incremental cancer detection attributable to integrated 2D and 3D mammography.
Fifty-nine cancers were detected in 57 patients: 20 cancers were found with integrated 2D and 3D versus none with 2D screening only. The cancer detection rates were 5.3 cancers per 1,000 screens when 2D alone was used and 8.1 cancers per 1,000 screens with integrated 2D and 3D screening. The incremental cancer detection rate attributable to integrated 2D and 3D mammography was 2.7 cancers per 1,000 screens.
False results were reported from a total of 395 screens: 181 at both screen reads, and 141 with 2D only, versus 73 with integrated 2D and 3D screening. The researchers estimated that conditional recall (positive integrated 2D and 3D mammography as a condition to recall) could have reduced false positive recalls by 17.2 percent without missing any of the cancers detected in the study population.
The researchers concluded that the integration of 2D and 3D mammography raised detection levels and that randomized controlled trials are needed for further investigation.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Mammography Study: AI Facilitates Greater Accuracy and Longer Fixation Time on Suspicious Areas
July 8th 2025While noting no differences in sensitivity, specificity or reading time with adjunctive AI for mammography screening, the authors of a new study noted a 4 percent higher AUC and increased fixation time on lesion regions.
Can Contrast-Enhanced Mammography be a Viable Screening Alternative to Breast MRI?
June 17th 2025While the addition of contrast-enhanced mammography (CEM) to digital breast tomosynthesis (DBT) led to over a 13 percent increase in false positive cases, researchers also noted over double the cancer yield per 1,000 women in comparison to DBT alone.
Contrast-Enhanced Mammography and High-Concentration ICM Dosing: What a New Study Reveals
June 16th 2025New research showed a 96 to 97 percent sensitivity for contrast-enhanced mammography (CEM) with an increased iodine delivery rate facilitating robust contrast enhancement for women with aggressive breast cancer.